Skip to content

TECO®Fast Candida IgG Lateral Flow Assay 

Key Features


Detection of Aspergillus IgG in 15 minutes, Sample material: serum.

Product Description



The Fast Candida IgG Ab Lateral Flow Assay (LFA) is used for the detection of Candida IgG antibody (Ab) in human serum samples. It can be used for clinical auxiliary diagnosis of Invasive Candidiasis.


  • Fluorescence-based lateral flow assays designed for readout via reader.
  • (Semi-)quantitative, calculation of calculation of IgG concentration in AU/mL and Mannan Antigen in pg/mL.
  • Validated for serum samples.
  • 2 results in 40 minutes obtained from 305 µL of serum.
  • Detection limit IgG: 7 AU/mL, cut-off value of 135 AU/mL.
  • Detection limit Antigen: 21.5 pg/mL, cut-off value of 60 pg/mL.
  • Increase in diagnostic significance through combination of two parameters.

Request Quotation


Product
SKU
Pack Size
Qty
TECO®Fast Candida IgG Lateral Flow Assay
SKU
TE1083
Pack Size
50 tests

Request Documentation


TECO®Fast Candida IgG Lateral Flow Assay
TE1083

Latest News


Meet Us At BioMedica!

Endopredict, a NICE-recommended in-vitro diagnostic test for determining the prognosis and treatment response of breast cancer.

The 2024 Emissions Report

As part of our commitment to sustainability, we partner with DHL to cut transport related emissions. Details available in our new 2024 Emissions Report!

New Brand to reflect growth, innovation, and a unified vision to become a leading global Specialty Diagnostics company

We are happy to announce that Eurobio Scientific UK will undertake a brand update to align with the evolving structure of the Eurobio Scientific Group.

This new brand embodies the collective strengths of all our affiliates, combining expertise and resources to create synergies to enhance our product offerings.

Navigating ER+ HER2- Early Breast Cancer

November 19, 2024 - Join us for the first seminar in our new series!

“Navigating ER+ HER2- Early Breast Cancer”

The session “What's new for high-risk early breast cancer patients” will focus on CDK4/6 inhibitors in the adjuvant setting for high-risk breast cancer patients, featuring a real-life case discussion and insights into the potential role of gene expression tests, including prospective validation data in high- risk patients (UNIRAD).

Contact Us